Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14% Seeking Alpha
Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14% Seeking Alpha
Aging has implications for a wide range of diseases. Researchers have been looking for ways to halt the aging process for millennia, but such methods remain elusive. Scientists at Harvard Medical School have now offered a glimmer of hope that the aging clock in the eye could be reversedat least in animals.
This article was originally published here Stem Cell Res Ther. 2020 Nov 30;11(1):516. doi: 10.1186/s13287-020-02037-3
This article was originally published here Cytotherapy.
The partnership will offer premium stem cell treatments for various degenerative diseases, immune disorders, injuries and anti-ageing. Thanyapura Sports and Health Resort, Phuket has partnered with StemCells21 (SC21), a medical biotech company based in Bangkok, Thailand
MELVILLE, N.Y., Nov.
Clinical trial results featured in last weeks news, some good and others not so good. Cytokinetics To continue reading The Pharma Letter please login,subscribeorclaim a 7 dayfree trial subscriptionand access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO and CMO, and regulation), then you can take our 10 per month channel subscription offer, which gives you access to all our news articles and in-depth content on this subject
MELVILLE, N.Y., Nov.
Novartis has licensed a new stem cell therapy from Mesoblast, just weeks after the FDA rejected the Australian biotechs pitch for an approval on a separate indication. The Swiss pharma announced Thursday afternoon it is partnering with Mesoblast $MESO to develop remestemcel-L for the treatment of acute respiratory distress syndrome, including ARDS related to Covid-19.
During a Targeted Oncology Case Based Peer Perspective event, Usama Gergis, MD, MBA, professor of Oncology, director, Bone Marrow Transplant and Immune Cellular Therapy at Sidney Kimmel Cancer Center, at the Thomas Jefferson University Hospital, discussed the case of a 48-year-old male patient with acute graft-versus-host-disease (GVHD). Targeted Oncology: For a patient such as this, what is the risk of developing acute (GVHD) following transplant
Recent Comments